Dashboard
Manage Tickers

MLTXMoonLake Immunotherapeutics

Nasdaq moonlaketx.com


$ 41.67 $ 1.50 (3.73 %)    

Thursday, 27-Jun-2024 15:59:50 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 482.07 $ 1.24 (0.26 %)
DIA $ 391.62 $ 0.32 (0.08 %)
SPY $ 546.37 $ 0.86 (0.16 %)
TLT $ 93.57 $ 0.37 (0.4 %)
GLD $ 215.08 $ 2.41 (1.13 %)
$ 41.69
$ 40.29
$ 0.00 x 0
$ 0.00 x 0
$ 40.29 - $ 42.22
$ 35.11 - $ 64.98
294,549
na
5.22B
$ 0.65
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-20-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 02-17-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-16-2021 06-30-2021 10-Q
13 05-21-2021 03-31-2021 10-Q
14 03-31-2021 12-31-2020 10-K
15 12-03-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

oppenheimer-initiates-coverage-on-moonlake-with-outperform-rating-announces-price-target-of-104
Oppenheimer Initiates Coverage On MoonLake...
06/25/2024 09:48:05

Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake (NASDAQ:MLTX) with a Outperform rating and announces Pr...

hc-wainwright--co-reiterates-buy-on-moonlake-maintains-100-price-target
HC Wainwright & Co. Reiterates Buy on Moon...
06/11/2024 10:35:44

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...

needham-reiterates-buy-on-moonlake-maintains-66-price-target
Needham Reiterates Buy on MoonLake, Mainta...
06/10/2024 17:49:09

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.

moonlake-immunotherapeutics-says-fda-and-ema-both-unanimously-support-cos-proposed-approach-for-advancing-its-phase-3-program-of-the-nanobody-sonelokimab-in-psoriatic-arthritis
MoonLake Immunotherapeutics Says FDA And E...
06/10/2024 12:04:21

hc-wainwright--co-reiterates-buy-on-moonlake-maintains-100-price-target
HC Wainwright & Co. Reiterates Buy on Moon...
05/17/2024 14:17:36

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...

moonlake-immunotherapeutics-begins-phase-3-vela-program-of-the-nanobody-sonelokimab-in-patients-with-moderate-to-severe-hidradenitis-suppurativa-topline-primary-endpoint-readout-at-week-16-together-with-data-on-other-endpoints-is-expected-as-of-mid-2025
Moonlake Immunotherapeutics Begins Phase 3...
05/16/2024 12:10:32

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidrad...

why-diodes-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Diodes Shares Are Trading Lower By Aro...
05/10/2024 16:44:44

hc-wainwright--co-reiterates-buy-on-moonlake-maintains-100-price-target
HC Wainwright & Co. Reiterates Buy on Moon...
05/08/2024 19:16:24

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...

needham-reiterates-buy-on-moonlake-maintains-66-price-target
Needham Reiterates Buy on MoonLake, Mainta...
05/08/2024 09:53:17

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.

moonlake-q1-eps-022-misses-020-estimate
MoonLake Q1 EPS $(0.22) Misses $(0.20) Est...
05/07/2024 12:09:48

MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by...

hc-wainwright--co-reiterates-buy-on-moonlake-maintains-100-price-target
HC Wainwright & Co. Reiterates Buy on Moon...
04/23/2024 10:26:47

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...

hc-wainwright--co-reiterates-buy-on-moonlake-maintains-100-price-target
HC Wainwright & Co. Reiterates Buy on Moon...
04/11/2024 11:27:28

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $100 price tar...

moonlake-immunotherapeutics-penned-three-year-technology-partnership-with-komodo-health-to-advance-research-on-inflammatory-skin-and-joint-conditions
Moonlake Immunotherapeutics Penned Three-y...
04/10/2024 11:06:15

needham-reiterates-buy-on-moonlake-maintains-66-price-target
Needham Reiterates Buy on MoonLake, Mainta...
04/09/2024 09:57:39

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:MLTX) with a Buy and maintains $66 price target.

goldman-sachs-initiates-coverage-on-moonlake-with-neutral-rating-announces-price-target-of-62
Goldman Sachs Initiates Coverage On MoonLa...
04/02/2024 11:05:50

Goldman Sachs analyst Richard Law initiates coverage on MoonLake (NASDAQ:MLTX) with a Neutral rating and announces Price Tar...

watching-moonlake-immunotherapeutics-shares-spike-higher-traders-circulate-comments-from-betaville
Watching MoonLake Immunotherapeutics; Shar...
03/28/2024 16:02:13

https://www.betaville.co.uk/betaville-intelligence/uncooked-alert-moonlake-immunotherapeutics-said-to/

wedbush-reiterates-outperform-on-moonlake-maintains-92-price-target
Wedbush Reiterates Outperform on MoonLake,...
03/13/2024 13:27:00

Wedbush analyst Andreas Argyrides reiterates MoonLake (NASDAQ:MLTX) with a Outperform and maintains $92 price target.

why-is-inflammatory-disease-focused-moonlake-immunotherapeutics-stock-trading-higher-today
Why Is Inflammatory Disease-Focused MoonLa...
03/11/2024 13:56:06

Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, a...

wedbush-reiterates-outperform-on-moonlake-maintains-92-price-target
Wedbush Reiterates Outperform on MoonLake,...
03/11/2024 12:48:29

Wedbush analyst Andreas Argyrides reiterates MoonLake (NASDAQ:MLTX) with a Outperform and maintains $92 price target.

hc-wainwright--co-maintains-buy-on-moonlake-raises-price-target-to-100
HC Wainwright & Co. Maintains Buy on MoonL...
03/11/2024 11:17:04

HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target f...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

06/28/2024 Malibu Boats, Inc. (MBUU)
07/01/2024 Globe Life Inc. f/k/a Torchmark Corporation (GL)
07/01/2024 Equinix, Inc. (EQIX)
07/02/2024 Intel Corporation (INTC)
07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)